Is Eos AI profitable in 2026?

No. Eos AI is a pre-seed, two-person startup with no disclosed revenue as of mid-2026. It reported a $500K pre-seed round led by Y Combinator and self-reported pilot metrics, but no named paying customers or signed contracts have been disclosed.

Could AI replace what Eos AI does?

Largely, yes. Eos AI's core functions, data harmonization and admin triage, are already shipped by rival Innovaccer's Gravity platform with 50+ prebuilt agents as of June 2026, and frontier models increasingly automate the same text and imaging structuring tasks.

Who is Eos AI's biggest competitor?

Innovaccer, which crossed $200M ARR in July 2026, has raised $675M total, works with 7 of the top 10 U.S. health systems, and manages 80 million patient records, dwarfing Eos AI's two-person, pre-seed operation.

Eos AI was founded in 2025 by Arya Khokhar (Caltech Math/CS, Stanford/Caltech clinical-AI research background), with Stanford Professor Kuo advising. It is backed by Y Combinator as part of the Winter 2026 (W26) batch; no other investors are publicly disclosed.

Has Eos AI had layoffs?

No layoffs are reported. Eos AI's team size is listed as just 2 people on Y Combinator's own jobs page as of 2026, consistent with a founding-stage startup rather than a company that has scaled and then cut staff.

Does Eos AI have any named hospital customers?

No named hospital or health-system customers have been publicly disclosed as of mid-2026. The company cites early pilot results (3x productivity, 37% revenue recovery) in its March 2026 YC launch, but these are self-reported, unverified vendor claims with no independent confirmation.

YC Winter 2026 · United States

Eos AI

Two-person startup building an autonomous data and admin OS for hospitals.

Little protection left

Assessed 27 July 2026 · Evidence as of 27 July 2026

Not much stands between this business and its pressures.

On the recordSince 27 July 2026 · Checkable from Q3 2027 · Every call on the record Checkpoint: Eos's $500K pre-seed runway (about 18 months) runs out, forcing a seed raise or shutdown

The call

Eos AI is a two-person, no-customer entrant trying to out-build a $200M-ARR incumbent and frontier AI labs on the same functions at once.

Eos AI is trying to sell hospital software that organizes messy medical data and handles routine administrative tasks like scheduling and billing. The problem is that Innovaccer already does this for seven of the ten biggest U.S. health systems and has much more money and customer data to prove it works. On top of that, large AI models are getting better at these exact tasks without needing special hospital software at all. The one thing that could matter is if Eos picks one narrow specialty (like cancer imaging or pharmacy work) and gets one major hospital to sign a real contract and commit to building with them over the next six months, which would prove customers actually need their approach instead of just using general AI tools.

Why

AI pressure: Frontier multimodal models (GPT-5, Gemini) absorbing harmonization and triage tasks. The same models Eos wraps around could natively do data harmonization, triage, and billing, cutting out the wrapper layer. Could AI do the core job? Yes, likely.

Bigger players: Innovaccer. Innovaccer already runs Gravity, 50+ prebuilt agents, in 7 of the top 10 US health systems with 80M patient records under management. Could a giant copy it? Yes, easily.

What protects it. None apparent: no named hospital customers, no signed contracts, no regulatory filings, and pilot metrics are self-reported.

What would change this call

Eos AI names a hospital design partner or signed pilot contract within 6 months. Would show Eos AI can win real customers despite Innovaccer's incumbency.
Eos AI raises a seed round beyond its $500K pre-seed within 6 months. Would show investor confidence and extended runway beyond the current 2-person team.
Eos AI narrows its positioning to pharma imaging or a single clinical specialty. Would show the founders are avoiding direct competition with Innovaccer's hospital footprint.

Key numbers

Innovaccer: $200M ARR (2026-07-23)
Innovaccer: 7 of top-10 US health systems (2026-07-23)
Eos AI: 2-person team, $500K pre-seed raised (2026-03-05)

Named risks

No named hospital customers or signed contracts disclosed as of mid-2026. Severity: high
Two-person team creates single point of failure; founder departure would be material. Severity: high
No proprietary data, regulatory cover, or deep EHR integrations identified as a moat. Severity: high
Category crowded with 50+ YC-backed peers plus scaled incumbent Innovaccer. Severity: medium
Core harmonization and triage functions overlap with capabilities frontier AI models already automate. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Innovaccer	losing to	Innovaccer at $200M ARR, 7 of top-10 US health systems, 80M records as of 2026-07-23 vs Eos's 2-person, pre-revenue stage
Abridge / Ambience Healthcare	contesting	Hold ~70% of the $600M 2025 ambient scribing market per Menlo Ventures, 2025-10-21
Triomics	contesting	Vendor-claimed trust from 4 of top-10 US cancer hospitals for oncology record processing, as of 2026-07-24
Cair Health	contesting	Vendor-claimed 100+ practices using its RCM AI agents, as of 2026-07-21

Questions people ask

Is Eos AI profitable in 2026?: No. Eos AI is a pre-seed, two-person startup with no disclosed revenue as of mid-2026. It reported a $500K pre-seed round led by Y Combinator and self-reported pilot metrics, but no named paying customers or signed contracts have been disclosed.
Could AI replace what Eos AI does?: Largely, yes. Eos AI's core functions, data harmonization and admin triage, are already shipped by rival Innovaccer's Gravity platform with 50+ prebuilt agents as of June 2026, and frontier models increasingly automate the same text and imaging structuring tasks.
Who is Eos AI's biggest competitor?: Innovaccer, which crossed $200M ARR in July 2026, has raised $675M total, works with 7 of the top 10 U.S. health systems, and manages 80 million patient records, dwarfing Eos AI's two-person, pre-seed operation.
Who owns Eos AI?: Eos AI was founded in 2025 by Arya Khokhar (Caltech Math/CS, Stanford/Caltech clinical-AI research background), with Stanford Professor Kuo advising. It is backed by Y Combinator as part of the Winter 2026 (W26) batch; no other investors are publicly disclosed.
Has Eos AI had layoffs?: No layoffs are reported. Eos AI's team size is listed as just 2 people on Y Combinator's own jobs page as of 2026, consistent with a founding-stage startup rather than a company that has scaled and then cut staff.
Does Eos AI have any named hospital customers?: No named hospital or health-system customers have been publicly disclosed as of mid-2026. The company cites early pilot results (3x productivity, 37% revenue recovery) in its March 2026 YC launch, but these are self-reported, unverified vendor claims with no independent confirmation.

Timeline

2026-07-23Rival Innovaccer reported to cross $200M ARR, 7 of top-10 US health systems
2026-03-16Fondo blog covers Eos AI's launch as Autonomous OS for hospitals
2026-03-12Industry newsletter counts 50+ YC-backed healthcare admin-automation startups
2026-03-05Eos AI publicly launches via Y Combinator, repositioned as Autonomous OS for hospitals
2025-12-28Eos AI selected for TechCrunch Disrupt 2025 Startup Battlefield 200
2025-01Eos AI founded by Arya Khokhar

Revision history

27 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

GRU Space Agentic Fabriq Vela